Original
Reactivación del virus de la hepatitis B en pacientes tratados con rituximab: incidencia y factores de riesgo
Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors
Leído
9209
Vecesse ha leído el artículo
1165
Total PDF
8044
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 11 | 1 | 12 |
| 2025 11 | 104 | 23 | 127 |
| 2025 10 | 100 | 7 | 107 |
| 2025 9 | 86 | 20 | 106 |
| 2025 8 | 97 | 28 | 125 |
| 2025 7 | 110 | 17 | 127 |
| 2025 6 | 103 | 6 | 109 |
| 2025 5 | 71 | 8 | 79 |
| 2025 4 | 81 | 8 | 89 |
| 2025 3 | 108 | 3 | 111 |
| 2025 2 | 86 | 4 | 90 |
| 2025 1 | 101 | 6 | 107 |
| 2024 12 | 91 | 4 | 95 |
| 2024 11 | 165 | 6 | 171 |
| 2024 10 | 99 | 6 | 105 |
| 2024 9 | 96 | 1 | 97 |
| 2024 8 | 107 | 9 | 116 |
| 2024 7 | 126 | 10 | 136 |
| 2024 6 | 101 | 13 | 114 |
| 2024 5 | 110 | 12 | 122 |
| 2024 4 | 71 | 12 | 83 |
| 2024 3 | 92 | 11 | 103 |
| 2024 2 | 86 | 7 | 93 |
| 2024 1 | 135 | 7 | 142 |
| 2023 12 | 95 | 4 | 99 |
| 2023 11 | 138 | 7 | 145 |
| 2023 10 | 131 | 13 | 144 |
| 2023 9 | 74 | 4 | 78 |
| 2023 8 | 83 | 5 | 88 |
| 2023 7 | 126 | 10 | 136 |
| 2023 6 | 96 | 17 | 113 |
| 2023 5 | 148 | 8 | 156 |
| 2023 4 | 106 | 4 | 110 |
| 2023 3 | 166 | 4 | 170 |
| 2023 2 | 94 | 7 | 101 |
| 2022 1 | 115 | 20 | 135 |
| 2022 12 | 57 | 11 | 68 |
| 2022 11 | 76 | 8 | 84 |
| 2022 10 | 64 | 25 | 89 |
| 2022 9 | 119 | 14 | 133 |
| 2022 8 | 89 | 16 | 105 |
| 2022 7 | 75 | 13 | 88 |
| 2022 6 | 74 | 15 | 89 |
| 2022 5 | 71 | 8 | 79 |
| 2022 4 | 55 | 17 | 72 |
| 2022 3 | 74 | 17 | 91 |
| 2022 2 | 51 | 6 | 57 |
| 2021 1 | 98 | 17 | 115 |
| 2021 12 | 44 | 16 | 60 |
| 2021 11 | 67 | 13 | 80 |
| 2021 10 | 77 | 19 | 96 |
| 2021 9 | 69 | 18 | 87 |
| 2021 8 | 60 | 8 | 68 |
| 2021 7 | 49 | 10 | 59 |
| 2021 6 | 69 | 15 | 84 |
| 2021 5 | 79 | 7 | 86 |
| 2021 4 | 127 | 12 | 139 |
| 2021 3 | 111 | 11 | 122 |
| 2021 2 | 86 | 7 | 93 |
| 2020 1 | 88 | 11 | 99 |
| 2020 12 | 64 | 9 | 73 |
| 2020 11 | 65 | 17 | 82 |
| 2020 10 | 81 | 11 | 92 |
| 2020 9 | 49 | 18 | 67 |
| 2020 8 | 57 | 9 | 66 |
| 2020 7 | 56 | 13 | 69 |
| 2020 6 | 65 | 20 | 85 |
| 2020 5 | 60 | 20 | 80 |
| 2020 4 | 56 | 10 | 66 |
| 2020 3 | 59 | 12 | 71 |
| 2020 2 | 83 | 12 | 95 |
| 2020 1 | 62 | 12 | 74 |
| 2019 12 | 67 | 6 | 73 |
| 2019 11 | 55 | 10 | 65 |
| 2019 10 | 64 | 13 | 77 |
| 2019 9 | 83 | 13 | 96 |
| 2019 8 | 56 | 9 | 65 |
| 2019 7 | 70 | 21 | 91 |
| 2019 6 | 134 | 14 | 148 |
| 2019 5 | 274 | 15 | 289 |
| 2019 4 | 116 | 18 | 134 |
| 2019 3 | 33 | 12 | 45 |
| 2019 2 | 41 | 14 | 55 |
| 2019 1 | 28 | 4 | 32 |
| 2018 12 | 27 | 9 | 36 |
| 2018 11 | 35 | 16 | 51 |
| 2018 10 | 53 | 15 | 68 |
| 2018 9 | 26 | 2 | 28 |
| 2018 8 | 19 | 3 | 22 |
| 2018 7 | 22 | 4 | 26 |
| 2018 6 | 25 | 10 | 35 |
| 2018 5 | 21 | 3 | 24 |
| 2018 4 | 23 | 2 | 25 |
| 2018 3 | 18 | 1 | 19 |
| 2018 2 | 4 | 1 | 5 |
| 2018 1 | 18 | 1 | 19 |
| 2017 12 | 15 | 3 | 18 |
| 2017 11 | 30 | 3 | 33 |
| 2017 10 | 21 | 4 | 25 |
| 2017 9 | 26 | 4 | 30 |
| 2017 8 | 25 | 3 | 28 |
| 2017 7 | 31 | 5 | 36 |
| 2017 6 | 36 | 11 | 47 |
| 2017 5 | 43 | 8 | 51 |
| 2017 4 | 37 | 9 | 46 |
| 2017 3 | 57 | 17 | 74 |
| 2017 2 | 20 | 9 | 29 |
| 2016 1 | 14 | 5 | 19 |
| 2016 12 | 1 | 2 | 3 |
| 2016 10 | 0 | 4 | 4 |
| 2016 9 | 0 | 1 | 1 |
| 2016 7 | 0 | 1 | 1 |
| 2016 6 | 0 | 1 | 1 |
| 2016 5 | 2 | 6 | 8 |
| 2016 2 | 0 | 2 | 2 |
| 2015 1 | 0 | 2 | 2 |
| 2015 12 | 2 | 1 | 3 |
| 2015 9 | 1 | 1 | 2 |
| 2015 8 | 1 | 0 | 1 |
| 2015 7 | 1 | 1 | 2 |
| 2015 6 | 1 | 1 | 2 |
| 2015 5 | 6 | 2 | 8 |
| 2015 4 | 2 | 3 | 5 |
| 2015 3 | 13 | 4 | 17 |
| 2015 2 | 16 | 9 | 25 |
| 2015 1 | 36 | 18 | 54 |
Mostrar todo
